TABLE 2.
Pivotal randomized controlled trials of perioperative chemotherapy for locally advanced gastric cancer
| Trial name | Country | NAC | Adjuvant | Primary endpoint | Control | Intervention | Hazard ratio (95% CI) | P value |
|---|---|---|---|---|---|---|---|---|
| JCOG0501 42 | Japan | CS | S‐1 | 3‐year OS | 62.4% | 60.9% | 0.916 (0.679‐1.236) | .28 |
| PRODIGY 45 | Korea | DOS | S‐1 | 3‐year PFS | 60.2% | 66.3% | 0.70 (0.52‐0.95) | .023 |
| RESONANCE 46 | China | SOX | SOX | 3‐year DFS | n/a | n/a | n/a | n/a |
| FLOT4‐AIO 47 | Germany | FLOT | FLOT | OS (MST) | 50 months | 35 months | 0.77 (0.63‐0.94) | .012 |
Abbreviations: CI, confidence interval; CS, S‐1 + cisplatin; DFS, disease‐free survival; DOS, docetaxel + oxaliplatin+S‐1; FLOT, fluorouracil + leucovorin+oxaliplatin + docetaxel; MST, mean survival time; n/a, not available; OS, overall survival; PFS, progression‐free survival; SOX, S‐1 + oxaliplatin.